Physician profile
Edmond E Pack
NPI 1043284334
$2,466.73
in general payments reported to CMS, 2019-2025
35 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $304 · 2021: $428 · 2022: $536 · 2023: $425 · 2024: $173 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.32 | 2019-2023 | |
| Therapeuticsmd, INC. | $208.08 | 2019-2022 | |
| Astellas Pharma US INC | $162.79 | 2023-2024 | Veozah |
| Mayne Pharma Commercial LLC | $156.63 | 2022-2025 | |
| Exeltis, USA INC. | $125.75 | 2020-2023 | Slynd |
| Coopersurgical, INC. | $119.08 | 2019-2024 | Paragard T 380a |
| Sage Therapeutics, LLC | $118.56 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $114.42 | 2019-2023 | |
| Hologic Sales and Service, LLC | $105.54 | 2019-2025 | Myosure Tissue Removal Device, Omni Hysteroscope, Aptima |
| Organon LLC | $79.14 | 2021-2023 | Nexplanon |
| Minerva Surgical, INC | $77.01 | 2019-2024 | |
| Daiichi Sankyo INC. | $68.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $49.80 | 2019-2024 | Gardasil 9, Gardasil |
| Momentis Surgical INC. | $48.00 | 2022 | |
| Medtronic, INC. | $40.16 | 2023 | Truclear |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $38.12 | 2021-2023 | Da Vinci Surgical System |
| Evofem Biosciences, INC. | $33.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $25.71 | 2021 | |
| Lupin INC. | $25.17 | 2020 | |
| Novo Nordisk INC | $24.85 | 2022 | |
| Sanofi Pasteur INC. | $22.69 | 2025 | |
| Shield Therapeutics INC | $18.88 | 2023 | Accrufer |
| Allergan, INC. | $18.41 | 2019 | |
| Uroviu Corporation | $15.93 | 2022 | |
| Solventum Corporation | $14.85 | 2025 | Prevena |
| Gynesonics, INC. | $14.34 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Olympus America INC. | $14.32 | 2023 | Olympus |
| Avion Pharmaceuticals | $13.54 | 2023 | Balcoltra |
| Myovant Sciences INC. | $13.53 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.82 | 2021 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edmond Pack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.